Table 1.
Patient characteristics and univariate analysis of overall survival
| Characteristics | Cases, N (%) | 5-year OS rate, % | P-value |
|---|---|---|---|
| Overall | 108 | 62.8 | |
| Age, years | 0.933 | ||
| <62 | 53 (49.1) | 60.8 | |
| ≥62 | 55 (50.9) | 65 | |
| Sex | 0.032 | ||
| Male | 48 (44.4) | 53.3 | |
| Female | 60 (55.6) | 72.7 | |
| Smoking status | 0.727 | ||
| Smoker | 37 (34.3) | 61.4 | |
| Never smoked | 71 (65.7) | 65.3 | |
| Concentration of CEA (μg/L) | 0.682 | ||
| <5 | 89 (82.4) | 62.4 | |
| ≥5 | 19 (17.6) | 66.6 | |
| Operating type | 0.059 | ||
| Lobectomy | 17 (15.7) | 49.1 | |
| Partial resection | 91 (84.3) | 66.5 | |
| IASLC/ATS/ERS classification risk group | 0.034 | ||
| Low risk | 13 (12.0) | 88.9 | |
| AAH | 1 (0.9) | ||
| AIS | 1 (0.9) | ||
| MIA | 1 (0.9) | ||
| Lepidic | 10 (9.3) | ||
| Moderate risk | 78 (71.3) | 64 | |
| Papillary | 30 (27.8) | ||
| Acinar | 47 (43.5) | ||
| High risk | 20 (16.7) | 36.3 | |
| Micropapillary | 4 (3.70) | ||
| Solid | 12 (11.1) | ||
| Mucinous | 2 (1.9) | ||
| Sica score | 0.032 | ||
| 0 or 2 or 3 | 12 (11.1) | 90.9 | |
| 4 | 52 (48.1) | 68.4 | |
| 5 or 6 | 44 (40.7) | 50.2 | |
| Differentiation | 0.679 | ||
| Well | 51 (47.2) | 72.9 | |
| Moderate | 47 (43.5) | 57.4 | |
| Poor | 10 (9.3) | 47.4 | |
| Pleural invasion | <0.001 | ||
| Absent | 94 (87) | 70.5 | |
| Present | 14 (13) | 18.4 | |
| Vascular invasion | <0.001 | ||
| Absent | 80 (74.1) | 70 | |
| Present | 28 (25.9) | 43.4 | |
| Lymph node metastasis | <0.001 | ||
| With | 7 (6.5) | 67.6 | |
| Without | 101 (93.5) | 38.1 | |
| TNM stage | <0.001 | ||
| 0 or I | 92 | 72.1 | |
| 0 | 2 (1.8) | 100 | |
| IA | 61 (56.5) | 82.3 | |
| IB | 29 (26.9) | 51.1 | |
| II | 13 | 20.5 | |
| IIA | 10 (9.3) | 45.0 | |
| IIB | 3 (2.8) | 33.3 | |
| IIIA | 3 (2.8) | 0 | |
| GalNAc-T3 expression | <0.001 | ||
| Low | 56 (51.9) | 45 | |
| High | 52 (48.1) | 82.3 |
Abbreviations: CEA, carcino-embryonic antigen; AAH, atypical adenomatous hyperplasia; AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; OS, overall survival; IASLC, International Association for the Study of Lung Cancer; ATS, the American Thoracic Society; ERS, European Respiratory Society; TNM, tumor-node-metastasis.